Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBLGOTCMKTS:NRIFFOTCMKTS:PVCTNASDAQ:RMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBLGFibroBiologics$0.87+0.3%$0.94$0.70▼$8.17$33.38M-0.8296,631 shs162,315 shsNRIFFNuvo Pharmaceuticals$0.00$0.30▼$0.87$8.52M1.577,337 shs3,000 shsPVCTProvectus Biopharmaceuticals$0.08-3.4%$0.09$0.04▼$0.17$32.07M0.78201,150 shs175,291 shsRMTIRockwell Medical$0.97-2.1%$1.05$0.86▼$5.15$33.21M1.61420,454 shs153,504 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBLGFibroBiologics-7.05%+2.38%0.00%-13.86%-88.89%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PVCTProvectus Biopharmaceuticals-6.51%+1.67%-10.02%-24.69%-51.83%RMTIRockwell Medical-3.66%-1.75%-4.59%-39.12%-47.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFBLGFibroBiologics3.2887 of 5 stars3.64.00.00.02.62.50.6NRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARMTIRockwell Medical4.3952 of 5 stars3.75.00.04.12.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBLGFibroBiologics 3.20Buy$13.001,389.97% UpsideNRIFFNuvo Pharmaceuticals 0.00N/AN/AN/APVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ARMTIRockwell Medical 3.33Buy$4.00311.61% UpsideCurrent Analyst Ratings BreakdownLatest NRIFF, RMTI, PVCT, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/24/2025RMTIRockwell MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $3.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBLGFibroBiologicsN/AN/AN/AN/A$0.04 per shareN/ANRIFFNuvo Pharmaceuticals$52.41M0.00N/A0.82$1.59 per share0.00PVCTProvectus Biopharmaceuticals$560K57.26N/AN/A($0.02) per share-3.82RMTIRockwell Medical$97.73M0.34$0.01 per share92.73$0.75 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBLGFibroBiologics-$16.49M-$0.21N/AN/AN/AN/AN/A-225.34%8/6/2025 (Estimated)NRIFFNuvo Pharmaceuticals$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/APVCTProvectus Biopharmaceuticals-$3.10MN/A0.00∞N/A-418.23%N/A-289.35%8/11/2025 (Estimated)RMTIRockwell Medical-$8.44M-$0.02N/AN/AN/A-1.25%8.55%3.80%8/6/2025 (Estimated)Latest NRIFF, RMTI, PVCT, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/A5/12/2025Q1 2025RMTIRockwell Medical-$0.03-$0.04-$0.01-$0.04$17.46 million$18.91 million3/31/2025Q4 2024FBLGFibroBiologics-$0.10-$0.09+$0.01-$0.09N/AN/A3/20/2025Q4 2024RMTIRockwell Medical$0.02-$0.02-$0.04-$0.02$23.65 million$24.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBLGFibroBiologicsN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ARMTIRockwell MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBLGFibroBiologicsN/A1.231.23NRIFFNuvo Pharmaceuticals5.272.672.11PVCTProvectus BiopharmaceuticalsN/A0.120.12RMTIRockwell Medical0.332.412.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBLGFibroBiologicsN/ANRIFFNuvo PharmaceuticalsN/APVCTProvectus Biopharmaceuticals0.05%RMTIRockwell Medical23.31%Insider OwnershipCompanyInsider OwnershipFBLGFibroBiologics20.00%NRIFFNuvo PharmaceuticalsN/APVCTProvectus Biopharmaceuticals14.70%RMTIRockwell Medical1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBLGFibroBiologics1038.26 million28.84 millionN/ANRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionablePVCTProvectus Biopharmaceuticals4420.28 million366.48 millionNot OptionableRMTIRockwell Medical30034.18 million31.71 millionOptionableNRIFF, RMTI, PVCT, and FBLG HeadlinesRecent News About These CompaniesBuy Rating for Rockwell Medical Amid Growth Potential and Market PositioningMay 19, 2025 | tipranks.comEarnings call transcript: Rockwell Medical Q1 2025 beats EPS forecast, stock jumpsMay 13, 2025 | uk.investing.comRockwell Medical, Inc. (NASDAQ:RMTI) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comQ1 2025 Rockwell Medical Inc Earnings CallMay 13, 2025 | finance.yahoo.comRockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...May 13, 2025 | gurufocus.comQ1 2025 Rockwell Medical Inc Earnings Call TranscriptMay 13, 2025 | gurufocus.comRockwell Medical’s Earnings Call: Navigating TransitionMay 12, 2025 | tipranks.comRockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comRockwell Medical Announces First Quarter 2025 ResultsMay 12, 2025 | businesswire.comRockwell Medical (RMTI) Q1 Revenue Exceeds Expectations Despite Sales DipMay 12, 2025 | gurufocus.comRockwell Medical Announces First Quarter 2025 Results | RMTI Stock NewsMay 12, 2025 | gurufocus.comRockwell Medical Inc Q1 2025 Earnings: EPS of -$0.05 Meets Estimates, Revenue of $18. ...May 12, 2025 | gurufocus.comRockwell Medical, Inc. (NASDAQ:RMTI) Major Shareholder Larson Family Inve Irrevocable Buys 57,000 SharesApril 16, 2025 | insidertrades.comRockwell Medical Investment Trust buys shares worth $94,017April 15, 2025 | investing.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025April 14, 2025 | gurufocus.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025 | RMTI Stock NewsApril 14, 2025 | gurufocus.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025April 14, 2025 | businesswire.comRockwell Medical stock target cut to $3 at H.C. WainwrightMarch 26, 2025 | investing.comRockwell Medical’s Growth Potential Amid Revenue Challenges: A Buy Rating by Ram SelvarajuMarch 24, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIFF, RMTI, PVCT, and FBLG Company DescriptionsFibroBiologics NASDAQ:FBLG$0.87 +0.00 (+0.29%) As of 04:00 PM EasternFibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Nuvo Pharmaceuticals OTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.08 0.00 (-3.42%) As of 01:36 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Rockwell Medical NASDAQ:RMTI$0.97 -0.02 (-2.07%) As of 04:00 PM EasternRockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
